Gain Therapeutics Welcomes New Chief Medical Officer

Photo of author
Written By Kris Enyinnaya

Gain Therapeutics, Inc. (NASDAQ: GANX), a biotechnology company focused on developing allosteric small-molecule therapies, announced Monday that Jonas Hannestad, M.D., Ph.D., has been appointed as its Chief Medical Officer since last Sunday.

Dr. Hannestad brings over two decades of experience in translational and early clinical development in the central nervous system (CNS) field, with a focus on neurodegenerative diseases such as Parkinson’s, Alzheimer’s, and ALS.

Background and Expertise of Dr. Hannestad

Prior to joining Gain, Dr. Hannestad held leadership roles at several biotechnology firms, including Tranquis Therapeutics and Capacity Bio. He has an extensive academic background, with positions at Yale School of Medicine, among others.

Credit: DepositPhotos

His expertise is expected to be a massive asset as Gain Therapeutics advances its lead drug candidate, GT-02287, through its ongoing Phase 1 clinical trial.

Read More: Exploring the Potential Value of Top-Performing Iris Energy Limited

GT-02287: A Hope for GBA1 Parkinson’s Disease

GT-02287 is being developed for the treatment of GBA1 Parkinson’s disease (GBA1-PD), a condition caused by mutations in the GBA1 gene and associated with a higher risk of Parkinson’s disease.

The drug aims to restore the function of the glucocerebrosidase enzyme, which is impaired due to the mutation. In preclinical studies, GT-02287 has shown promise in reducing biomarkers and symptoms of neurodegeneration.

Strategic Appointment and Stock Options

In connection with his appointment, Dr. Hannestad was granted an option to purchase 200,000 shares of Gain Therapeutics’ common stock at $4.06 per share, with a vesting period over four years.

Also Read: Farmers & Merchants Bancorp: A Steady Performer in the Banking Sector

Advancing CNS Therapeutics

This announcement comes as part of Gain Therapeutics’ broader efforts to develop therapies for untreatable or difficult-to-treat disorders, leveraging its Magellan™ drug discovery platform that combines AI, proprietary algorithms, and supercomputer-powered physics-based models.

Financial and Market Overview

Gain Therapeutics Inc welcomes Dr. Jonas Hannestad as its new Chief Medical Officer, the company’s financial metrics and market performance provide additional context to its operational updates.

With a market capitalization of approximately $64.88 million, the company is navigating through a challenging fiscal period. The latest data indicates that Gain Therapeutics is trading at a high revenue valuation multiple, with a price-to-book ratio as of the last twelve months of Q4 2023 standing at 4.86.

Analysts’ Optimism and Financial Challenges

Analysts appear to be optimistic about the company’s sales growth in the current year, which could be a positive sign for the future trajectory of GT-02287, its lead drug candidate.

However, they also note that the company is not expected to be profitable this year and has been quickly burning through cash, which underscores the importance of strategic leadership in the drug development process.

Gain’s Financial Strategy and Market Performance

Despite these financial challenges, Gain Therapeutics holds more cash than debt on its balance sheet and has liquid assets that exceed short-term obligations, which may provide some financial flexibility as it pushes forward with clinical trials.

Credit: DepositPhotos

The company’s stock performance reflects a strong return over the last three months, with a 15.47% price total return, although it has fared poorly over the last month with a -19.44% price total return.

Read Next: This Company Has a Strong Dividend Yield – But Is It Sustainable?


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.